Question 1

What is the Meaning of MORE Trial?

Accepted Answer

The MORE Trial, or Multiple Outcomes of Raloxifene Evaluation, was a landmark clinical study investigating raloxifene, a selective estrogen receptor modulator (SERM). This extensive, randomized, placebo-controlled trial rigorously assessed its impact on bone mineral density, fracture incidence, and invasive breast cancer risk in postmenopausal women with osteoporosis, providing foundational evidence for therapeutic guidelines.

Question 2

What is the Context of MORE Trial?

Accepted Answer

This trial addresses crucial aspects of postmenopausal hormonal physiology, specifically the skeletal and mammary gland responses to estrogen decline. Raloxifene functions by tissue-selectively modulating estrogen receptors within the endocrine system. Understanding this precise interaction is vital for clinicians managing bone health and mitigating specific cancer risks in this population.

Question 3

What is the Significance of MORE Trial?

Accepted Answer

The MORE Trial definitively established raloxifene's efficacy in reducing vertebral fractures and lowering invasive breast cancer risk among postmenopausal women with osteoporosis. Its findings provided a robust, evidence-based treatment option, offering a unique dual benefit for skeletal fragility and breast cancer prevention, profoundly influencing patient care and clinical practice.

Question 4

What is the Mechanism of MORE Trial?

Accepted Answer

Raloxifene acts as a selective estrogen receptor modulator, exhibiting agonist activity in bone tissue and antagonist activity in breast and uterine tissues. In bone, it mimics estrogen's protective effects, inhibiting osteoclast-mediated bone resorption and preserving bone mineral density. Its antagonistic action in breast tissue suppresses estrogen-dependent cellular proliferation, contributing to cancer risk reduction.

Question 5

What is the Application of MORE Trial?

Accepted Answer

Clinically, raloxifene is prescribed for the prevention and treatment of osteoporosis in postmenopausal women, particularly those at heightened risk for invasive breast cancer. It is typically administered orally once daily. Patients receiving this therapy undergo routine clinical evaluations, including bone density monitoring, to confirm therapeutic effectiveness and address any emergent concerns.

Question 6

What is the Metric of MORE Trial?

Accepted Answer

Outcomes related to the MORE Trial are primarily assessed via bone mineral density (BMD) measurements using dual-energy X-ray absorptiometry (DXA) scans of the lumbar spine and hip. The incidence of new fractures, especially vertebral fractures, serves as a critical clinical endpoint. Serum biomarkers of bone turnover, such as CTX or P1NP, can also offer supplementary insights into treatment response.

Question 7

What is the Risk of MORE Trial?

Accepted Answer

While generally well-tolerated, raloxifene, as demonstrated by the MORE Trial, carries an elevated risk of venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, particularly early in treatment. Other potential adverse effects include hot flashes and leg cramps. Raloxifene is contraindicated in individuals with a history of VTE or during pregnancy and lactation.

MORE Trial

Meaning

Context

Significance

Mechanism

Application

Metric

Risk

What Are the Long-Term Cardiovascular Effects of SERMs?

What Are the Long-Term Safety Profiles of SERMs in Postmenopausal Women?

Provided by the clinical team
at 4Ever Young Miami Dadeland

-15% ∞ HRTIO15

Your protocol begins with a conversation.

Visit

Schedule Appointment

About

Med & Wellness

4Ever Young Miami Dadeland

Communication

+1 786-529-6686

Email Us

Opening Hours